FDA
-
-
-
-
-
-
-
Unicycive Therapeutics (UNCY) PT Raised to $18 at Benchmark
-
-
-
-
-
-
-
Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Five Below, Inc. (NASDAQ: FIVE); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grab
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Avantor, Inc. (NYSE: AVTR); Five Below, Inc. (NASDAQ: FIVE); Molina Healthcare, Inc. (NYSE: MOH); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); Treace Medical Concepts (NASDAQ: TMCI); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar
-
-
-
-
-
-
-
Important Notice to Long-Term Shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT); Lantheus Holdings, Inc. (NASDAQ: LNTH); Savara Inc. (NASDAQ: SVRA); and Unicycive Therapeutics, Inc. (NASDAQ
-
326,421 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

